More importantly, FIBP was found to be expressed at higher levels in saracatinib-resistant CRC than in saracatinib-sensitive cancer based on further in-depth analysis of Gene Expression Omnibus (GEO) datasets (GSE36006)31. The gene discussed is FIBP; the disease is colorectal carcinoma.